N-acetyltransferase multiplicity and the bioactivation of N-arylhydroxamic acids by hamster hepatic and intestinal enzymes.
The mechanism-based inactivation (suicide inactivation) by N-hydroxyphenacetin (NHP) of N-arylhydroxamic acid N,O-acyltransferase (AHAT) and p-aminobenzoic acid N-acetyltransferase (PABA NAT) activities of a partially purified hamster liver preparation was investigated. The inactivation of both enzyme activities was irreversible, but a partial protection of PABA NAT could be achieved by inclusion of the nucleophile cysteine in the incubation mixture; cysteine did not reduce the extent of inactivation of AHAT by NHP. Hepatic AHAT and PABA NAT activities were separated by affinity chromatography, and the resolved enzyme activities were subjected to incubation in the presence of NHP, N-hydroxy-2-acetamidofluorene (N-OH-AAF), and N-hydroxy-4-acetamidobiphenyl (N-OH-AABP); AHAT, but not PABA NAT, was inactivated by NHP, N-OH-AAF and N-OH-AABP. Incubation of hamster heptic PABA NAT with radiolabeled N-OH-AAF resulted in the formation of only 15% as much fluorenylamine-tRNA adduct as was formed when N-OH-AAF was bioactivated with hamster hepatic AHAT. Hamster intestinal AHAT and PABA NAT activities also were resolved by affinity chromatography; the intestinal AHAT fractions were much more effective than the PABA NAT fractions in bioactivating N-OH-AAF. These results demonstrate that hamster liver and intestine contain at least two arylamine transacetylating activities, one of which is much more effective than the other in the bioactivation of toxic and carcinogenic N-arylhydroxamic acids.
D015073:2-Acetylaminofluorene / Q000031:analogs & derivatives*; D010129:4-Aminobenzoic Acid / Q000378:metabolism*; D000107:Acetylation; D000123:Acetyltransferases / Q000032:analysis* / Q000037:antagonists & inhibitors; D000217:Acyltransferases / Q000032:analysis*; D062365:Aminobenzoates / Q000378:metabolism*; D000818:Animals; D001711:Biotransformation; D002273:Carcinogens / Q000378:metabolism*; D002846:Chromatography, Affinity; D006224:Cricetinae; D006881:Hydroxyacetylaminofluorene / Q000378:metabolism / Q000494:pharmacology*; D007422:Intestines / Q000201:enzymology*; D008099:Liver / Q000201:enzymology*; D008297:Male; D008647:Mesocricetus; D010615:Phenacetin / Q000031:analogs & derivatives* / Q000494:pharmacology; D012343:RNA, Transfer / Q000378:metabolism; D010128:p-Aminoazobenzene / Q000378:metabolism
D062365:Aminobenzoates; D002273:Carcinogens; C008068:N-hydroxyphenacetin; D006881:Hydroxyacetylaminofluorene; D010128:p-Aminoazobenzene; D012343:RNA, Transfer; D015073:2-Acetylaminofluorene; D000217:Acyltransferases; D000123:Acetyltransferases; C019736:N-hydroxyarylamine O-acetyltransferase; D010615:Phenacetin; D010129:4-Aminobenzoic Acid